Accident Compensation Corp increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,097 shares of the biopharmaceutical company’s stock after purchasing an additional 5,436 shares during the period. Gilead Sciences accounts for about 1.4% of Accident Compensation Corp’s holdings, making the stock its 25th biggest holding. Accident Compensation Corp’s holdings in Gilead Sciences were worth $5,031,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in the stock. Welch Investments LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at about $108,000. Horan Capital Advisors LLC. acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $147,000. Hanson & Doremus Investment Management raised its stake in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 480 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (GILD) traded up $1.10 during trading hours on Monday, reaching $79.32. 13,746,101 shares of the company were exchanged, compared to its average volume of 9,867,733. The company has a market capitalization of $104,800.00, a PE ratio of 23.04, a price-to-earnings-growth ratio of -1.77 and a beta of 1.22. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The firm’s revenue for the quarter was down 18.7% compared to the same quarter last year. During the same period last year, the firm posted $2.70 earnings per share. research analysts predict that Gilead Sciences, Inc. will post 6.41 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
A number of equities research analysts have recently issued reports on GILD shares. JPMorgan Chase & Co. set a $85.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Mizuho upped their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. William Blair restated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and a consensus target price of $87.04.
In related news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares in the company, valued at approximately $224,302,912.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 358,333 shares of company stock valued at $28,066,908 over the last 90 days. 1.30% of the stock is currently owned by insiders.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.